• Users Online: 2675
  • Print this page
  • Email this page

 Table of Contents    
Year : 2011  |  Volume : 55  |  Issue : 2  |  Page : 104-110  

Ropivacaine: A review of its pharmacology and clinical use

1 Department of Anesthesia and Critical Care, SPS Apollo Hospitals, Ludhiana, India
2 Department of Clinical Pharmacology, SPS Apollo Hospitals, Ludhiana, India

Date of Web Publication22-Apr-2011

Correspondence Address:
Gaurav Kuthiala
Department of Anesthesia and Critical Care, SPS Apollo Hospitals, Ludhiana - 141 003
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5049.79875

Rights and Permissions

Ropivacaine is a long-acting amide local anaesthetic agent and first produced as a pure enantiomer. It produces effects similar to other local anaesthetics via reversible inhibition of sodium ion influx in nerve fibres. Ropivacaine is less lipophilic than bupivacaine and is less likely to penetrate large myelinated motor fibres, resulting in a relatively reduced motor blockade. Thus, ropivacaine has a greater degree of motor sensory differentiation, which could be useful when motor blockade is undesirable. The reduced lipophilicity is also associated with decreased potential for central nervous system toxicity and cardiotoxicity. The drug displays linear and dose proportional pharmacokinetics (up to 80 mg administered intravenously). It is metabolised extensively in the liver and excreted in urine. The present article details the clinical applications of ropivacaine and its current place as a local anaesthetic in the group.

Keywords: Anaesthesia, regional anaesthetic, ropivacaine

How to cite this article:
Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth 2011;55:104-10

How to cite this URL:
Kuthiala G, Chaudhary G. Ropivacaine: A review of its pharmacology and clinical use. Indian J Anaesth [serial online] 2011 [cited 2021 Jun 20];55:104-10. Available from: https://www.ijaweb.org/text.asp?2011/55/2/104/79875

   Introduction Top

One of the most important properties of a long-acting local anaesthetic is to reversibly inhibit the nerve impulses, thus causing a prolonged sensory or motor blockade appropriate for anaesthesia in different types of surgeries. [1] The acute pain relief obtained at lower doses in postoperative and labour patients due to sensory blockade is sometimes marred by accompanying motor blockade, which serves no purpose and is quite undesirable.

Bupivacaine is a well-established long-acting regional anaesthetic, which like all amide anaesthetics has been associated with cardiotoxicity when used in high concentration or when accidentally administered intravascularly. Ropivacaine is a long-acting regional anaesthetic that is structurally related to Bupivacaine. It is a pure S(-)enantiomer, unlike Bupivacaine, which is a racemate, developed for the purpose of reducing potential toxicity and improving relative sensory and motor block profiles. [1]

   Stereospecificity and Structure Top

Enantiomers exist in two different spatial configurations, like right- and left-handed gloves, and are present in equal amounts in a racemic solution. They are optically active and can be differentiated by their effects on the rotation of the plane of a polarised light into dextrorotatory [clockwise rotation (R+)] or levorotatory [counterclockwise rotation (S-)] stereoisomers. The physicochemical properties of the two enantiomeric molecules are identical, but the two enantiomers can have substantially different behaviours in their affinity for either the site of action or the sites involved in the generation of side effects. R(+) and S(-) enantiomers of local anaesthetics have been demonstrated to have different affinity for different ion channels of sodium, potassium, and calcium; this results in a significant reduction in central nervous system (CNS) and cardiac toxicity (cardiotoxicity) of the S(-)enantiomer as compared with the R(+)enantiomer. [2]

The technological advancements have made it possible to develop Ropivacaine as an optically pure S(-) enantiomeric from the parent chiral molecule propivacaine. It belongs to the group of local anaesthetics, the pipecoloxylidides and has a propyl group on the piperidine nitrogen atom compared to bupivacaine, which has a butyl group. [3]

   Mechanism of Action Top

Ropivacaine causes reversible inhibition of sodium ion influx, and thereby blocks impulse conduction in nerve fibres. [1] This action is potentiated by dose-dependent inhibition of potassium channels. [4] Ropivacaine is less lipophilic than bupivacaine and is less likely to penetrate large myelinated motor fibres; therefore, it has selective action on the pain-transmitting A δ and C nerves rather than Aβ fibres, which are involved in motor function.

   Pharmacodynamics Top

CNS and cardiovascular effects

Ropivacaine is less lipophilic than bupivacaine and that, together with its stereoselective properties, [5] contributes to ropivacaine having a significantly higher threshold for cardiotoxicity and CNS toxicity than bupivacaine in animals [5],[6] and healthy volunteers. [7]

The lower lipophilicity of ropivacaine versus bupivacaine correlated with the lesser cardiodepressant effects of both ropivacaine isomers than of the bupivacaine isomers in animal studies. [5]

The CNS effects occurred earlier than cardiotoxic symptoms during an intravenous (IV) infusion of local anaesthetic (10 mg/min of ropivacaine or bupivacaine) in human volunteers and the infusion was stopped at this point. Significant changes in cardiac function involving the contractility, conduction time and QRS width occurred and the increase in a QRS width was found to be significantly smaller with ropivacaine than with bupivacaine. [8],[9]

Other effects

Ropivacaine has been shown to inhibit platelet aggregation in plasma at concentrations of 3.75 and 1.88 mg/mL (0.375% and 0.188%), which correspond to those that could occur in the epidural space during infusion. [10] Like other anaesthetics, ropivacaine has antibacterial activity in vitro, inhibiting the growth of Staphylococcus aureus, [11],[12] Escherichia More Details coli, [11] and Pseudomonas aeruginosa.[12]

   Pharmacokinetics Top

Absorption and distribution

The plasma concentration of ropivacaine depends on the total dose administered and the route of administration, as well as the haemodynamic and circulatory condition of the patient and vascularity of the administration site. [13]

When ropivacaine was administered intravenously in subjects, its pharmacokinetics were linear and dose proportional up to 80 mg. [13] The absorption of ropivacaine 150 mg from the epidural space is complete and biphasic.The mean half-life of the initial phase is approximately 14 minutes, followed by a slower phase with a mean absorption t 1/2 of approximately 4.2 hours.

Ropivacaine is bound to plasma proteins to an extent of 94%, mainly to α1-acid glycoprotein. The total plasma concentration increase during continuous epidural infusion of ropivacaine [13],[14] is caused by an increase in the degree of protein binding and subsequent decrease in clearance of ropivacaine. [14]

Ropivacaine rapidly crosses the placenta during epidural administration for caesarean section, resulting in near complete equilibrium of the free fraction of ropivacaine in the maternal and foetal circulation. [15] However, the total plasma concentration of ropivacaine was lower in the foetal circulation than in the maternal circulation, reflecting the binding of ropivacaine to α1-acid glycoprotein, which is more concentrated in maternal than in foetal plasma.

Metabolism and excretion

Ropivacaine is metabolised extensively in the liver, predominantly by aromatic hydroxylation to 3′-hydroxy-ropivacaine by cytochrome P450 (CYP) 1A2 and N-dealkylation to 2′,6′-pipecoloxylidide by CYP3A4. [16],[17] The kidney is the main excretory organ for ropivacaine, accounting for 86% of the excretion of the drug in urine after a single intravenous dose administration. It has a mean±SD terminal half-life of 1.8±0.7 h and 4.2±1.0 h after intravenous and epidural administration, respectively.

Relative potency

A strict correlation exists between the lipid solubility of the local anaesthetic and its potency and toxicity. According to minimum local anaesthetic concentration (MLAC) studies, which are based on effective analgesia in 50% of patients) ropivacaine has similar potency to bupivacaine at higher doses (eg, doses required for peripheral nerve blocks for surgical anaesthesia), ropivacaine is less potent than bupivacaine and levobupivacaine at lower doses, such as those used for epidural or intrathecal analgesia. Providing anaesthesia or analgesia for the majority of patients is more clinically relevant than the MLAC and, at higher doses used in clinical practice, this potency difference is not always evident.


Reactions to ropivacaine are characteristic of those associated with other amide-type local anaesthetics.

a. In adults

Ropivacaine is generally well tolerated regardless of the route of administration. [13] In a pooled analysis of data from controlled clinical trials adverse events that occurred in ≥5% of patients who received ropivacaine 0.125-1% via various routes of administration for surgery, labour, Caesarean section, postoperative pain management, peripheral nerve block or local infiltration (n=1,661) were hypotension (32%), nausea (17%), vomiting (7%), bradycardia (6%), and headache (5%). [13] These events are a consequence of nerve block and occurred with similar incidence in patients (n=1433) who received bupivacaine 0.25-0.75% for same indications (29%, 14%, 6%, 5%, and 5%, respectively). [13]

Epidural administration of ropivacaine for surgery generally produced dose-dependent adverse events similar to those observed with equal doses of bupivacaine. [13]

The incidence of ropivacaine-induced cardiovascular symptoms may be age-related; [18] patients aged ≥61 years who received epidural ropivacaine 1% had a significantly higher incidence of bradycardia ([58%] vs [15%] patients aged 41-60 years; P=0.005) and hypotension ([74%] vs [20%] patients aged 18-40 years; P=0.002). [18] The cardiovascular events are also related to toxicity due to sudden IV injection or massive absorption from peripheral nerve blocks.

b. In children

Ropivacaine was generally well tolerated in paediatric patients aged from 1 month to 15 years regardless of the route of administration. [19] The overall incidence of adverse events associated with ropivacaine appeared to be low, [19] with nausea and/or vomiting occurring most frequently. [19]

c. In exposed foetuses and neonates

Ropivacaine was generally well tolerated in the foetus or neonate following the use of regional anaesthesia in women undergoing Caesarean section or during labour. [13] The most common foetal or neonatal adverse events with ropivacaine were foetal bradycardia (12%), neonatal jaundice (8%), and unspecified neonatal complications (7%). These events occurred with similar frequency with bupivacaine (12%, 8%, and 7%, respectively). [13]

According to a meta-analysis of six double-blind trials, ropivacaine did not influence the neonatal neurological and adaptive capacity (NAC) score at 2 hours after delivery and, at 24 hours after delivery, total NAC scores were significantly higher in neonates whose mothers had received ropivacaine rather than bupivacaine (P<0.05). [20]

   Cardiotoxicity and CNS Toxicity in Comparison to Bupivacaine Top

The incidence of cardiotoxicity and central nervous system (CNS) toxicity as a result of inadvertent intravascular injection of ropivacaine appears to be low. [21] According to a pooled analysis of data from ≈3000 patients in 60 clinical studies, the incidence of probable accidental IV injection of ropivacaine was ≈0.2% (six patients) and only one patient experienced convulsions; no patient showed symptoms of cardiotoxicity. [21]

The convulsive local anaesthetic doses of bupivacaine and ropivacaine were studied in different animal models; bupivacaine has a 1.5- to 2.5-fold lower convulsive threshold when compared to ropivacaine. On the basis of animal and volunteer studies, it can be concluded that ropivacaine seems to be less neurotoxic and cardiotoxic than bupivacaine.

   Drug Interactions Top

Ropivacaine should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics, since the toxic effects of these drugs are additive.

Cytochrome P4501A2 metabolises ropivacaine to 3-hydroxy ropivacaine, the major metabolite. Thus, strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of ropivacaine, can interact with ropivacaine and thus lead to increased ropivacaine plasma levels. Caution should be exercised when co-administering CYP1A2 inhibitors. Possible interactions with drugs known to be metabolised by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. [22]

   Dosage Top

The dosage recommendations for ropivacaine in various indications and procedures are summarised in [Table 1].
Table 1: Dosage recommendations for ropivacaine in adults and children

Click here to view

   Clinical Applications Top

Numerous clinical trials have evaluated the efficacy of ropivacaine for surgical anaesthesia, for labour pain and postoperative pain in adults and children. The drug has been compared primarily with bupivacaine or levobupivacaine. In the recent years, the use of ropivacaine in the management of chronic pain has also been evaluated in various modalities.

Surgical anaesthesia

Clinical trials indicate that ropivacaine is an effective regional anaesthetic when administered via several routes.

Epidural administration

Epidural ropivacaine, administered primarily in the lumbar region, has an effect of anaesthetic for a number of surgical procedures. A majority of studies on epidural ropivacaine are in Caesarean section and although the drug has been investigated as an anaesthetic agent for other abdominal or gynaecological procedures, orthopaedic and vascular surgery, the major use of epidural ropivacaine in the latter procedures is for postoperative pain relief.

a. Caesarean section

Clinical trials of epidural anaesthesia for elective Caesarean section indicate that ropivacaine (0.75% or 0.5%) [23] provides a clinically similar onset of sensory and motor block to that of bupivacaine 0.5%. [23] The median duration of analgesia within dermatomes relevant for surgery (T6-S3) was 1.7-4.2 hours for ropivacaine and 1.8-4.4 hours for bupivacaine, but the median duration of complete motor block was significantly longer with bupivacaine than with ropivacaine (2.5 vs 0.9 hours, P<0.05). [23]

b. Hip or lower limb surgery

In patients undergoing lumbar epidural anaesthesia for lower limb surgery, ropivacaine provided a similar anaesthetic profile (with regard to onset of analgesia or anaesthesia and onset of motor block) to those of levobupivacaine [24] or bupivacaine. [25] A 20-ml dose of ropivacaine 0.5% or bupivacaine 0.5% also resulted in a median duration of T10 sensory block of 3.5 versus 3.4 hours, and 15% versus 18% of patients with complete motor block. [25]

   Intrathecal Administration Top

Single doses of 2-4 ml of 0.5%-2% solutions of ropivacaine have been shown to be less potent than bupivacaine when administered intrathecally and is generally administered at a higher dose than bupivacaine. Hyperbaric solutions of ropivacaine have been compared to isobaric solution of the drug for various procedures and generally resulted in a faster onset and recovery from the blocks. Although hyperbaric solutions of ropivacaine appear to provide a more predictable block, the spread and duration of the block varies markedly. Hyperbaric ropivacaine solutions are not commercially available. Comparative trials in patients undergoing elective Caesarean section receiving ropivacaine 12 mg, levobupivacaine 8 mg, or bupivacaine 8 mg, all with sufentanil 2.5 μg showed similar times to onset of analgesia, but significantly shorter time to recovery from sensory and motor block was observed with ropivacaine and levobupivacaine as compared to bupivacaine. [26] The co-administration of opioids reduces the total dose of local anaesthetic required for anaesthesia and significantly prolongs the duration of complete and effective analgesia without prolonging the duration of motor block. [27]

In a trial involving lower limb surgeries the duration of sensory block with ropivacaine 15 mg was found to be similar with bupivacaine 10 mg, and the motor block was significantly shorter, it was also suggested that on a milligram for milligram basis, the potency of ropivacaine relative to bupivacaine is two-thirds with regard to sensory block and half with regard to motor block. [28]

   Peripheral Nerve Blocks Top

Peripheral nerve block is employed for anaesthesia for orthopaedic surgery, and the onset and spread of local anaesthetic is influenced by the site of injection. [29] The long-acting sensory and motor block provided by ropivacaine is 0.5% or 0.75% for axillary, interscalene and subclavian perivascular brachial plexus block for hand or arm surgery compared favourably with bupivacaine 0.5% [29],[30],[31],[32],[33] or levobupivacaine 0.5% (30-45 ml bolus dose) with a similar quality of regional anaesthesia. In lower limb surgeries where sciatic or combined femoral and sciatic block was given for knee, ankle, or foot procedures, ropivacaine 0.75% (25 ml) had a significantly faster onset of sensory and motor block than 25 ml bupivacaine 0.5%. Although ropivacaine had a significantly shorter duration of sensory block, the duration of motor block remained similar with both agents. [34]

   Management of Postoperative Pain Top

Lower doses of local anaesthetics are generally required for postoperative pain relief than for anaesthesia.

Epidural administration

Ropivacaine is administered epidurally (via lumbar or thoracic route) for postoperative pain following abdominal (upper or lower), gynaecological, orthopaedic and other surgeries.

a. Following abdominal surgery

The efficacy of epidural ropivacaine has been compared with intravenous morphine, epidural bupivacaine, and ropivacaine in combination with fentanyl.

Ropivacaine, with or without morphine, was more effective at relieving postoperative pain than intravenous morphine alone. [35]

b. Following orthopaedic surgery

Patients who had undergone hip arthroplasty had significantly more effective pain relief with epidural ropivacaine than with intravenous morphine (primary endpoint) and supplementary analgesia was administered to numerically more patients in the morphine group than in the ropivacaine group. [36]

In patients who had undergone knee arthroplasty, [37] pain relief with epidural ropivacaine 0.2% was not as effective as bupivacaine 0.2%, and although there were no significant differences between groups for the number of patients recording visual analog scale (VAS) scores >30 mm at rest, more patients in the ropivacaine group than in the bupivacaine group reported VAS scores >30 mm for pain on movement during 8-24 hours post surgery. However, in another study comparing ropivacaine with bupivacaine in patients who had undergone hip arthroplasty, [38] the significantly lower incidence of motor block in ropivacaine recipients was accompanied by similarly effective pain relief among treatment groups and greater patient satisfaction. [38],[39]

Nerve blocks

a. Following upper limb surgery

There was similar pain relief with ropivacaine and bupivacaine, [40] although hand strength returned more quickly and there was less paraesthesia of the fingers in patients receiving ropivacaine than in those receiving bupivacaine. [40] At 24 hours after the block, hand strength (primary endpoint) reduced by 48% in ropivacaine recipients and 66% in bupivacaine recipients (P<0.05). Further, 6 hours after discontinuation of the infusion, hand strength was fully restored in the ropivacaine group but still decreased by 25% in the bupivacaine group (P<0.05). [40]

b. Following lower limb surgery

Patients who received combined femoral and sciatic nerve block [41] with ropivacaine to facilitate foot/ankle [41] surgery had similar or better postoperative pain relief and a longer duration of analgesia than recipients of mepivacaine.

   Management of Labour Pain Top

Epidurally administered ropivacaine is effective in providing relief from labour pain. It is recommended to administer 10-20 ml bolus of ropivacaine 0.2% with intermittent 20-30 mg top up injections or a continuous epidural infusion of ropivacaine 0.2% (6-10 ml/hr) for labour analgesia. The analgesic efficacy of ropivacaine is similar to or slightly less than bupivacaine. The difference between the incidences of operative deliveries when ropivacaine was compared with bupivacaine was also not found significant.

The addition of narcotics like fentanyl 2 μg/ml to ropivacaine 0.1% solution administered at 10 ml/hr significantly reduces local anaesthetic concentration, as the quality of analgesia is similar to ropivacaine 0.2%-only solution or ropivacaine 0.2% plus fentanyl 2 ΅g/ml infused at a slower rate of 8 ml/hr. [42] Addition of adjuvants like clonidine also significantly increases the duration of action of ropivacaine.

Intrathecally administered ropivacaine as a part of combined spinal epidural technique produces rapid and effective labour pain relief with less incidence of motor block. [43]

   Ropivacaine and Chronic Pain Management Top

Lierz et al. compared the analgesic, motor block, and haemodynamic effects of single-shot epidural injections of ropivacaine 0.2% 10 mL with bupivacaine 0.125% in outpatients suffering from chronic low back pain in a randomised study involving 36 patients. Bupivacaine 0.125% and ropivacaine 0.2% showed no significant differences in analgesia or in motor blockade or haemodynamic changes. Both appear suitable for epidural administration to outpatients with chronic low back pain attending for epidural analgesia associated with physiotherapy. [44] In another study, the prophylactic effectiveness of ropivacaine injections in migraine was studied during a 12-week period. A total of 52 patients participated in the study. Trigger points were explored by palpitation and injected weekly with 10 mg ropivacaine. In nine patients (17.3%), the frequency of attacks was reduced ≥50%, and in 19 cases (36.5%), the reduction was between 11% and 49%. A total of 31 patients (59.6%) reported to be much or very much improved after completing the injection period. Trigger points inactivation can be an effective palliative measure in the prophylactic management of severe refractory migraine. [45]

   Conclusion Top

Ropivacaine is a well tolerated regional anaesthetic effective for surgical anaesthesia as well as the relief of postoperative and labour pain. The efficacy of ropivacaine is similar to that of bupivacaine and levobupivacaine for peripheral nerve blocks and, although it may be slightly less potent than bupivacaine when administered epidurally or intrathecally, equi-effective doses have been established. Clinically adequate doses of ropivacaine appear to be associated with a lower incidence or grade of motor block than bupivacaine. Thus, ropivacaine, with its efficacy, lower propensity for motor block, and reduced potential for CNS toxicity and cardiotoxicity, appears to be an important option for regional anaesthesia and management of postoperative and labour pain.

   References Top

1.Hansen TG. Ropivacaine: A pharmacological review. Expert Rev Neurother 2004;4:781-91.  Back to cited text no. 1
2.Aberg G. Toxicological and local anesthetic effects of optically active isomers of two local anesthetic compounds. Acta Pharmacol Toxicol Scand1972;31:273-86.  Back to cited text no. 2
3.McClure JH. Ropivacaine. Br J Anaesth 1995;76:300-7.  Back to cited text no. 3
4.Kindler CH, Paul M, Zou H, Liu C, Winegar BD, Gray AT, et al. Amide local anaesthetics potently inhibit the human tandem pore domain background K+ channel TASK-2 (KCNK5). J Pharmacol Exp Ther 2003;306:84-92.  Back to cited text no. 4
5.Graf BM, Abraham I, Eberbach N, Kunst G, Stowe DF, Martin E. Differences in cardiotoxicity of bupivacaine and ropivacaine are the result of physicochemical and stereoselective properties. Anesthesiology 2002;96:1427-34.  Back to cited text no. 5
6.Dony P, Dewinde V, Vanderick B, Cuignet O, Gautier P, Legrand E, et al. The comparative toxicity of ropivacaine and bupivacaine at equipotent doses in rats. Anesth Analg 2000;91:1489-92.  Back to cited text no. 6
7.Knudsen K, Beckman Suurküla M, Blomberg S, Sjövall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997;78:507-14.   Back to cited text no. 7
8.0 Graf BM. The cardiotoxicity of local anesthetics: The place of ropivacaine. Curr Top Med Chem 2001;1:207-14.  Back to cited text no. 8
9.Cederholm I, Evers H, Löfström JB. Skin blood flow after intradermal injection of ropivacaine in various concentrations with and without epinephrine evaluated by laser Doppler flowmetry. Reg Anesth 1992;17:322-8.  Back to cited text no. 9
10.Porter J, Crowe B, Cahill M, Shorten G. The effects of ropivacaine hydrochloride on platelet function: An assessment using the platelet function analyser (PFA-100). Anaesthesia 2001;56:15-8.  Back to cited text no. 10
11.Bátai I, Kerényi M, Falvai J, Szabó G. Bacterial growth in ropivacaine hydrochloride. Anesth Analg 2002;94:729-31.  Back to cited text no. 11
12.Kampe S, Poetter C, Buzello S, Wenchel HM, Paul M, Kiencke P, et al. Ropivacaine 0.1% with sufentanil 1 microg/mL inhibits in vitro growth of Pseudomonas aeruginosa and does not promote multiplication of Staphylococcus aureus. Anesth Analg 2003;97:409-11.  Back to cited text no. 12
13.Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine: A review of its use in regional anaesthesia and acute pain management. Drugs 2005;65:2 675-717.  Back to cited text no. 13
14.Burm AG, Stienstra R, Brouwer RP, Emanuelsson BM, van Kleef JW. Epidural infusion of ropivacaine for postoperative analgesia after major orthopedic surgery: Pharmacokinetic evaluation. Anesthesiology 2000;93:395-403.  Back to cited text no. 14
15.Ala-Kokko TI, Alahuhta S, Jouppila P, Korpi K, Westerling P, Vähäkangas K. Feto-maternal distribution of ropivacaine and bupivacaine after epidural administration for cesarean section. Int J Obstet Anesth 1997;6:147-52.  Back to cited text no. 15
16.Ekstrom G, Gunnarsson UB. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996;24:955-61.  Back to cited text no. 16
17.Lee A, Fagan D, Lamont M, Tucker GT, Halldin M, Scott DB. Disposition kinetics of ropivacaine in humans. Anesth Analg 1989;69:736-8.th   Back to cited text no. 17
18. Simon MJ, Veering BT, Stienstra R, van Kleef JW, Burm AG. The effects of age on neural blockade and hemodynamic changes after epidural anesthesia with ropivacaine. Anesth Analg 2002;94:1325-30.  Back to cited text no. 18
19.Bosenberg A, Thomas J, Lopez T, Lybeck A, Huizar K, Larsson LE. The efficacy of caudal ropivacaine 1, 2 and 3mg/ml for postoperative analgesia in children. Paediatr Anaesth 2002;12:53-8.  Back to cited text no. 19
20.Writer WD, Stienstra R, Eddleston JM, Gatt SP, Griffin R, Gutsche BB, et al. Neonatal outcomes and mode of delivery after epidural analgesia with ropivacaine and bupivacaine: A prospective meta-analysis. Br J Anaesth 1998;81:713-7.  Back to cited text no. 20
21.Selander D, Sjovall J, Waldenlind L . Accidental i.v injections of ropivacaine: Clinical experience of six cases [abstract]. Reg Anaesth 1997;22:70.  Back to cited text no. 21
22.Jokinen MJ, Olkkola KT, Ahonen J, Neuvonen PJ. Effect of rifampin and tobacco smoking on the pharmacokinetics of ropivacaine. Clin Pharmacol Ther 2001;70:344-50.  Back to cited text no. 22
23.Crosby E, Sandler A, Finucane B, Writer D, Reid D, McKenna J, et al. Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarian section. Can J Anaesth 1998;45:1066-71.  Back to cited text no. 23
24.Peduto VA, Baroncini S, Montanini S, Proietti R, Rosignoli L, Tufano R, et al. A prospective, randomized, double-blind comparison of epidural levobupivacaine 0.5% with epidural ropivacaine 0.75% for lower limb procedures. Eur J Anaesthesiol 2003;20:979-83.  Back to cited text no. 24
25.McGlade DP, Kalpokas MV, Mooney PH, Buckland MR, Vallipuram SK, Hendrata MV, et al. Comparison of 0.5% ropivacaine and 0.5% bupivacaine in lumbar epidural anaesthesia for lower limb orthopaedic surgery. Anaesth Intensive Care 1997;25:262-6.  Back to cited text no. 25
26.Gautier P, De Kock M, Huberty L, Demir T, Izydorczic M, Vanderick B. Comparison of the effects of intrathecal ropivacaine, levobupivacaine, and bupivacaine for caesarean section. Br J Anaesth 2003;91:684-9.  Back to cited text no. 26
27.Chung CJ, Yun SH, Hwang GB, Park JS, Chin YJ. Intrathecal fentanyl added to hyperbaric ropivacaine for cesarean delivery. Reg Anesth Pain Med 2002;27:600-3.  Back to cited text no. 27
28.Kallio H, Snäll EV, Kero MP, Rosenberg PH. A comparison of intrathecal plain solutions containing ropivacaine 20 or 15 mg versus bupivacaine 10 mg. Anesth Analg 2004;99:713-7.  Back to cited text no. 28
29.Hofmann-Kiefer K, Herbrich C, Seebauer A, Schwender D, Peter K. Ropivacaine 7.5 mg/ml versus bupivacaine 5 mg/ml for interscalene brachial plexus block: A comparative study. Anaesth Intensive Care 2002;30:331-7.  Back to cited text no. 29
30.Casati A, Borghi B, Fanelli G, Montone N, Rotini R, Fraschini G, et al. Interscalene brachial plexus anesthesia and analgesia for open shoulder surgery: A randomized, double-blinded comparison between levobupivacaine and ropivacaine. Anesth Analg 2003;96:253-9.  Back to cited text no. 30
31.Vaghadia H, Chan V, Ganapathy S, Lui A, McKenna J, Zimmer K. A multicentre trial of ropivacaine 7.5 mg/ml(-1) vs bupivacaine 5 mg/ml (-) for supraclavicular brachial plexus anesthesia. Can J Anaesth 1999;46:946-51.  Back to cited text no. 31
32.Raeder JC, Drøsdahl S, Klaastad O, Kvalsvik O, Isaksen B, Strømskag KE, et al. Axillary brachial plexus block with ropivacaine 7.5 mg/mL: A comparative study with bupivacaine 5 mg/mL. Acta Anaesthesiol Scand 1999;43:794-8.  Back to cited text no. 32
33.Liisanantti O, Luukkonen J, Rosenberg PH. High-dose bupivacaine, levobupivacaine and ropivacaine in axillary brachial plexus block. Acta Anaesthesiol Scand 2004;48:601-6  Back to cited text no. 33
34.Fanelli G, Casati A, Beccaria P, Aldegheri G, Berti M, Tarantino F, et al. A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg 1998;87:597-600.  Back to cited text no. 34
35.Jayr C, Beaussier M, Gustafsson U, Leteurnier Y, Nathan N, Plaud B, et al. Continuous epidural infusion of ropivacaine for postoperative analgesia after major abdominal surgery: Comparative study with i.v. PCA morphine. Br J Anaesth 1998;81:887-92.  Back to cited text no. 35
36.Wulf H, Biscoping J, Beland B, Bachmann-Mennenga B, Motsch J. Ropivacaine epidural anesthesia and analgesia versus general anesthesia and intravenous patient-controlled analgesia with morphine in the perioperative management of hip replacement. Ropivacaine Hip Replacement Multicenter Study Group. Anesth Analg 1999;89:111-6.  Back to cited text no. 36
37.Muldoon T, Milligan K, Quinn P, Connolly DC, Nilsson K. Comparison between extradural infusion of ropivacaine or bupivacaine for the prevention of postoperative pain after total knee arthoplasty. Br J Anaesth 1998;80:680-1.  Back to cited text no. 37
38.Bertini L, Mancini S, Di Benedetto P, Ciaschi A, Martini O, Nava S, et al. Postoperative analgesia by combined continuous infusion and patient-controlled epidural analgesia (PCEA) following hip replacement: Ropivacaine versus bupivacaine. Acta Anaesthesiol Scand 2001;45:782-5.  Back to cited text no. 38
39.Lorenzini C, Moreira LB, Ferreira MB. Efficacy of ropivacaine compared with ropivacaine plus sufentanil for postoperative analgesia after major knee surgery. Anaesthesia 2002;57:424-8.  Back to cited text no. 39
40.Borgeat A, Kalberer F, Jacob H, Ruetsch YA, Gerber C. Patient-controlled intercaine scalene analgesia with ropivacaine 0.2% versus bupivacaine 0.15% after major open shoulder surgery: The effects on hand motor function. Anesth Analg 2001;92:218-23.  Back to cited text no. 40
41.Fanelli G, Casati A, Beccaria P, Aldegheri G, Berti M, Tarantino F, et al. A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg 1998;87:597-600.  Back to cited text no. 41
42.Atienzar MC, Palanca JM, Borras R, Esteve I, Fernandez M, Miranda A. Ropivacaine 0.1% with fentanyl 2 microg mL(-1) by epidural infusion for labour analgesia. Eur J Anaesthesiol 2004;21:770-5.  Back to cited text no. 42
43.Levin A, Datta S, Camann WR. Intrathecal ropivacaine for labor analgesia: A comparison with bupivacaine. Anesth Analg 1998;87:624-7.  Back to cited text no. 43
44.Lierz P, Gustorff B, Markow G, Felleiter P. Comparison between bupivacaine 0.125% and ropivacaine 0.2% for epidural administration to outpatients with chronic low back pain. Eur J Anaesthesiol 2004;21:32-7.  Back to cited text no. 44
45.García-Leiva JM, th Hidalgo J, th Rico-Villademoros F, th Moreno V, th Calandre EP. Effectiveness of ropivacaine trigger points inactivation in the prophylactic management of patients with severe migraine. th Pain Med 2007;8:65-70.  Back to cited text no. 45


  [Table 1]

This article has been cited by
1 Ropivacaine relieves pain and prevents chondrocyte degradation probably through Calcineurin/NFAT1 signaling pathway in osteoarthritis rats
Wenyu Yao,Qian Han,Lei Wang,Zhiqiang Niu
European Journal of Pharmacology. 2018; 818: 518
[Pubmed] | [DOI]
2 Randomized controlled study of intraincisional infiltration versus intraperitoneal instillation of standardized dose of ropivacaine 0.2% in post-laparoscopic cholecystectomy pain: Do we really need high doses of local anesthetics—time to rethink!
Singh Mathuria Kaushal-Deep,Afzal Anees,Shehtaj Khan,Mohammad Amanullah Khan,Mehershree Lodhi
Surgical Endoscopy. 2018;
[Pubmed] | [DOI]
3 Continuous adductor canal block added to local infiltration analgesia (LIA) after total knee arthroplasty has no additional benefits on pain and ambulation on postoperative day 1 and 2 compared with LIA alone
Svava Gudmundsdottir,Jonas L Franklin
Acta Orthopaedica. 2017; : 1
[Pubmed] | [DOI]
4 Intraoperative instillation of ropivacaine during the placement of sub-muscular cosmetic breast implants: Is there a clinical benefit?
F. Picard,J. Niddam,A. De Runz,M. Chaouat,M. Mimoun,D. Boccara
Annales de Chirurgie Plastique Esthétique. 2017;
[Pubmed] | [DOI]
5 Postoperative Analgesia After Wound Infiltration With Tramadol and Dexmedetomidine as an Adjuvant to Ropivacaine for Lumbar Discectomies
Saikat Mitra,Shobha Purohit,Mamta Sharma
Journal of Neurosurgical Anesthesiology. 2017; 29(4): 433
[Pubmed] | [DOI]
6 Effect of local wound infiltration with ropivacaine on postoperative pain relief and stress response reduction after open hepatectomy
Jing-Xian Sun,Ke-Yun Bai,Yan-Feng Liu,Gang Du,Zhi-Hao Fu,Hao Zhang,Jin-Huan Yang,Ben Wang,Xiu-Yu Wang,Bin Jin
World Journal of Gastroenterology. 2017; 23(36): 6733
[Pubmed] | [DOI]
7 Ropivacaine and Bupivacaine prevent increased pain sensitivity without altering neuroimmune activation following repeated social defeat stress
Caroline M. Sawicki,January K. Kim,Michael D. Weber,Brant L. Jarrett,Jonathan P. Godbout,John F. Sheridan,Michelle Humeidan
Brain, Behavior, and Immunity. 2017;
[Pubmed] | [DOI]
8 Effectiveness of Bupivacaine Liposome Injectable Suspension for Postoperative Pain Control in Total Knee Arthroplasty: A Prospective, Randomized, Double Blind, Controlled Study
Jeffrey H. DeClaire,Paige M. Aiello,Olayinka K. Warritay,Dwight C. Freeman
The Journal of Arthroplasty. 2017;
[Pubmed] | [DOI]
9 Percutaneous ultrasound-guided vs. intraoperative rectus sheath block for pediatric umbilical hernia repair: A randomized clinical trial
Cristen N. Litz,Sandra M. Farach,Allison M. Fernandez,Richard Elliott,Jenny Dolan,Nikhil Patel,Lillian Zamora,Paul M. Colombani,Nebbie E. Walford,Ernest K. Amankwah,Christopher W. Snyder,Paul D. Danielson,Nicole M. Chandler
Journal of Pediatric Surgery. 2017;
[Pubmed] | [DOI]
10 Ultrasound-guided femoral and obturator nerves block in the psoas compartment in dogs: anatomical and randomized clinical study
Hamaseh Tayari,Giulio Tazioli,Gloria Breghi,Angela Briganti
Veterinary Anaesthesia and Analgesia. 2017;
[Pubmed] | [DOI]
11 Analgésie après reconstruction du ligament croisé antérieur : infiltration du site de prélèvement des ischio-jambiers versus injection intra-articulaire
B. Sonnery-Cottet,A. Saithna,A. Azeem,E. Choudja,J.B. Pic,J. Cabaton,M. Thaunat
Revue de Chirurgie Orthopédique et Traumatologique. 2017; 103(2): 156
[Pubmed] | [DOI]
12 Comparison of postoperative pain control methods after bony surgery in the foot and ankle
Chan Kang,Gi-Soo Lee,Sang-Bum Kim,You-Gun Won,Jeong-Kil Lee,You-Sun Jung,Hyung-June Cho
Foot and Ankle Surgery. 2017;
[Pubmed] | [DOI]
13 Analgesia after ACL reconstruction: Hamstring donor-site injection versus intra-articular local anaesthetic injection
B. Sonnery-Cottet,A. Saithna,A. Azeem,E. Choudja,J.B. Pic,J. Cabaton,M. Thaunat
Orthopaedics & Traumatology: Surgery & Research. 2016;
[Pubmed] | [DOI]
14 Peri-incisional and intraperitoneal ropivacaine administration: a new effective tool in pain control after laparoscopic surgery in gynecology: a randomized controlled clinical trial
Carlo Saccardi,Salvatore Gizzo,Amerigo Vitagliano,Marco Noventa,Massimo Micaglio,Matteo Parotto,Mauro Fiorese,Pietro Litta
Surgical Endoscopy. 2016;
[Pubmed] | [DOI]
15 Novel methods of local anesthetic delivery in the perioperative and postoperative setting—potential for fibrin hydrogel delivery
Laura Kearney,Derek Whelan,Brian D. OæDonnell,Anthony J.P. Clover
Journal of Clinical Anesthesia. 2016; 35: 246
[Pubmed] | [DOI]
16 Anesthetic Management Guided by Transthoracic Echocardiography During Cesarean Delivery Complicated by Hypertrophic Cardiomyopathy
Jaclyn M. DesRoches,Dolores Madeline McKeen,Andrew Warren,Victoria M. Allen,Ronald B. George,Catherine Kells,Romesh Shukla
A & A Case Reports. 2016; 6(6): 154
[Pubmed] | [DOI]
17 Incidence of cardiovascular complications in knee arthroplasty patients before and after implementation of a ropivacaine local infiltration analgesia protocol: A retrospective study
Joost R.C. Lameijer,Frederik Verboom,Joost Grefkens,Joris Jansen
The Knee. 2016;
[Pubmed] | [DOI]
18 Transversus abdominis plane block for postoperative pain relief after hand-assisted laparoscopic colon surgery: a randomized, placebo-controlled clinical trial
R. Tikuisis,P. Miliauskas,V. Lukoseviciene,N. Samalavicius,A. Dulskas,L. Zabuliene,V. Zabulis,J. Urboniene
Techniques in Coloproctology. 2016;
[Pubmed] | [DOI]
19 Use of a perineural coiled catheter at the sciatic nerve in dogs after tibial plateau levelling osteotomy - preliminary observations
Vincent Marolf,Cédric Luyet,Claudia Spadavecchia,Urs Eichenberger,Ulrich Rytz,Helene Rohrbach
Veterinary Medicine and Science. 2015; 1(2): 39
[Pubmed] | [DOI]
20 Ropivacaine and dexamethasone: a potentially dangerous combination for therapeutic pain injections
Trevor William Watkins,Simon Dupre,John Richard Coucher
Journal of Medical Imaging and Radiation Oncology. 2015; 59(5): 571
[Pubmed] | [DOI]
21 Intrathecal Analgesia for Chronic Refractory Pain: Current and Future Prospects
Catherine Smyth,Nadera Ahmadzai,Jason Wentzell,Ashley Pardoe,Andrew Tse,Tiffany Nguyen,Yvette Goddard,Shona Nair,Patricia A. Poulin,Becky Skidmore,Mohammed T. Ansari
Drugs. 2015; 75(17): 1957
[Pubmed] | [DOI]
22 Prospective, randomized controlled trial on use of ropivacaine after robotic thyroid surgery: Effects on postoperative pain
Dong Sik Bae,Su-jin Kim,Do Hoon Koo,Se-Hyun Paek,Hyungju Kwon,Young Jun Chai,June Young Choi,Kyu Eun Lee,Yeo-Kyu Youn
Head & Neck. 2015; : n/a
[Pubmed] | [DOI]
23 Effects of Ropivacaine on Postoperative Pain and Peak Expiratory Flow Rate in Patients Undergoing Percutaneous Nephrolithotomy
Farsad Imani,Somayyeh Zamani,Farhad Etezadi,Reza Shariat Moharari,Mohammad Reza Khajavi,Seyed Reza Hosseini
Nephro-Urology Monthly. 2015; 7(6)
[Pubmed] | [DOI]
24 Liposomal bupivacaine – New trends in Anesthesia and Intensive Care Units
Alexandru Florin Rogobete,Ovidiu Horea Bedreag,Mirela Sarandan,Marius Papurica,Gabriela Preda,Maria Corina Dumbuleu,Corina Vernic,Emil Robert Stoicescu,Dorel Sandesc
Egyptian Journal of Anaesthesia. 2015;
[Pubmed] | [DOI]
25 Reducing the Dose of Local Anesthetic Reduces the Duration of Analgesia—Myth or Reality: A Double-Blind Randomized Study
Piacherski Valery,Marachkou Aliaksei
Open Journal of Anesthesiology. 2015; 05(01): 7
[Pubmed] | [DOI]
26 Ropivacaine: a new local anaesthetic agent in maxillofacial surgery
A. Budharapu,R. Sinha,U.K. Uppada,A.V.S.S. Subramanya Kumar
British Journal of Oral and Maxillofacial Surgery. 2015; 53(5): 451
[Pubmed] | [DOI]
27 The benefits of preincision ropivacaine infiltration for reducing postoperative pain after robotic bilateral axillo-breast approach thyroidectomy: a prospective, randomized, double-blind, placebo-controlled study
Kyung Ho Kang,Byung Seup Kim,Hyun Kang
Annals of Surgical Treatment and Research. 2015; 88(4): 193
[Pubmed] | [DOI]
28 Sparing Effects of Sufentanil on Epidural Ropivacaine in Elderly Patients Undergoing Transurethral Resection of Prostate Surgery
Huiling Li,Yuhong Li,Rui He
Yonsei Medical Journal. 2015; 56(3): 832
[Pubmed] | [DOI]
29 Epidural anesthesia for pilonidal sinus surgery: ropivacaine versus levobupivacaine
Zeynep Nur Orhon,Emine Nursen Koltka,Sibel Devrim,Sevil Tüfekçi,Serkan Dogru,Melek Çelik
Korean Journal of Anesthesiology. 2015; 68(2): 141
[Pubmed] | [DOI]
30 Comparison of the effects of intra-articular sole ropivacaine and combined ketorolac and ropivacaine for pain control after knee arthroscopy surgery
Faranak Rokhtabnak,Mahmood Reza Ale Bouyeh,Alireza Seyed Siamdust,Mehdi Masoomshahi,Marjan Aghajani
British Journal of Pain. 2015; 9(3): 149
[Pubmed] | [DOI]
31 Seizures following accidental intravascular injection of ropivacaine through epidural catheter
CL Gurudatta,HS Harshavardhana
Indian Journal of Anaesthesia. 2015; 59(2): 123
[Pubmed] | [DOI]
32 Safety of liposome extended-release bupivacaine for postoperative pain control
Juan Portillo,Nawal Kamar,Somayah Melibary,Eduardo Quevedo,Sergio Bergese
Frontiers in Pharmacology. 2014; 5
[Pubmed] | [DOI]
33 Neurotoxic effects of local anesthetics on the mouse neuroblastoma NB2a cell line
M Mete,I Aydemir,IM Tuglu,M Selcuki
Biotechnic & Histochemistry. 2014; : 1
[Pubmed] | [DOI]
34 Comparison between lignocaine hydrochloride and ropivacaine hydrochloride as lumbosacral epidural anaesthetic agents in goats undergoing laparoscopy assisted embryo transfer
Anubhav Khajuria,Mujeeb Fazili ur R.,Riaz Shah A.,Maajid Bhat H.,Firdous Khan A.,Syed Yaqoob H.,Niyaz Naykoo A.,Nazir Ganai A.
Macedonian Veterinary Review. 2014; 37(2): 141
[Pubmed] | [DOI]
35 Total systemic ropivacaine concentrations following aerosolized intraperitoneal delivery using the AeroSurge
Ailbhe M. McDermott,Kah Hoong Chang,Kelly Mieske,Abdelaly Abeidi,Brian H. Harte,Michael J. Kerin,Oliver J. McAnena
Journal of Clinical Anesthesia. 2014;
[Pubmed] | [DOI]
36 Comparing the effectiveness of ropivacaine 0.5% versus ropivacaine 0.2% for transabdominis plane block in providing postoperative analgesia after appendectomy
Reymi Marseela Abdul Jalil,Nurlia Yahya,Omar Sulaiman,Wan Rahiza Wan Mat,Rufinah Teo,Azarinah Izaham,Raha Abdul Rahman
Acta Anaesthesiologica Taiwanica. 2014;
[Pubmed] | [DOI]
37 Comparison of Two Doses of Ropivacaine Hydrochloride for Lumbosacral Epidural Anaesthesia in Goats Undergoing Laparoscopy Assisted Embryo Transfer
Anubhav Khajuria,Mujeeb ur Rehman Fazili,Riaz Ahmad Shah,Firdous Ahmad Khan,Maajid Hassan Bhat,Syed Hilal Yaqoob,Niyaz Ahmad Naykoo,Nazir Ahmad Ganai
International Scholarly Research Notices. 2014; 2014: 1
[Pubmed] | [DOI]
38 Ropivacaine in ultrasound-guided femoral nerve block: what is the minimal effective anaesthetic concentration (EC90)?
A. M. Taha,A. M. Abd-Elmaksoud
Anaesthesia. 2014; : n/a
[Pubmed] | [DOI]
39 Local anesthesia for treatment of hernia in elder patients: Levobupicavaine or Bupivacaine?
Rita Compagna,Gabriele Vigliotti,Tommaso Bianco,Maurizio Amato,Roberto Rossi,Francesca Fappiano,Antonello Accurso,Michele Danzi,Giovanni Aprea,Bruno Amato
BMC Surgery. 2013; 13(Suppl 2): S30
[Pubmed] | [DOI]
40 Onset of labor epidural analgesia with ropivacaine and a varying dose of fentanyl: a randomized controlled trial
E.C. Bang,H.S. Lee,Y.I. Kang,K.S. Cho,S.Y. Kim,H. Park
International Journal of Obstetric Anesthesia. 2012; 21(1): 45
[Pubmed] | [DOI]
41 Comparative study between Levobupivacaine and Bupivacaine for hernia surgery in the elderly
Compagna, R. and Vigliotti, G. and Coretti, G. and Amato, M. and Aprea, G. and Puzziello, A. and Militello, C. and Iacono, F. and Prezioso, D. and Amato, B.
BMC Surgery. 2012; 12(SUPPL. 1)
42 Onset of labor epidural analgesia with ropivacaine and a varying dose of fentanyl: A randomized controlled trial
Bang, E.C., Lee, H.S., Kang, Y.I., Cho, K.S., Kim, S.Y., Park, H.
# # International Journal of Obstetric Anesthesia. 2012; 21(1): 45-50
43 Midazolam in rabbits terminates dysrhythmias caused by intracerebroventricular ropivacaine
Zhu, Y.-M., Yuan, Z.-Y., Wu, H., Zhou, D.-D., Jing, G.-X.
Journal of Zhejiang University: Science B. 2011; 12(8): 668-676
44 Midazolam in rabbits terminates dysrhythmias caused by intracerebroventricular ropivacaine
Yao-min Zhu,Zu-yi Yuan,Hui Wu,Dan-dan Zhou,Gui-xia Jing
Journal of Zhejiang University SCIENCE B. 2011; 12(8): 668
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Mechanism of Action
    Cardiotoxicity a...
    Drug Interactions
    Clinical Applica...
    Intrathecal Admi...
    Peripheral Nerve...
    Management of Po...
    Management of La...
    Ropivacaine and ...
    Article Tables

 Article Access Statistics
    PDF Downloaded5588    
    Comments [Add]    
    Cited by others 44    

Recommend this journal